RMTG’s Cellgenic launches MUSE cell product line in international markets
RMTG•Cellgenic expands MUSE cell line internationally
Regenerative Medical Technology Group launched a MUSE cell product line via Cellgenic for selected international markets, subject to local rules.
The expansion targets Latin America, the Middle East, Europe and Southeast Asia, positioning Cellgenic to widen its addressable physician base.
The rollout follows an NK cell product launch on Aug. 24, signaling a repeatable pipeline that could support faster market entry.
Management framed the cadence of differentiated launches as a competitive advantage, aiming to build operating leverage across its supply business.
